NCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
Clinical Trials
48 trialsNCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT05870748 2025-09-23
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Sutro Biopharma, Inc.
Phase 2/3 Terminated
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02569957 2025-05-04
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT01904253 2024-09-05
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT02649673 2023-12-05
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
SCRI Development Innovations, LLC
Phase 1 Terminated
NCT04455139 2023-10-03
EuRbG2018
University of Lausanne Hospitals
Phase 2 Terminated
NCT01076400 2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT03927274 2023-05-25
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Terminated
NCT02963090 2023-02-15
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
Alliance Foundation Trials, LLC.
Phase 2 Terminated
NCT00014443 2023-01-09
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Rush University Medical Center
Phase 2 Terminated
NCT04022876 2022-10-10
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Aileron Therapeutics, Inc.
Phase 1 Terminated
NCT01803269 2020-06-26
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
University of Chicago
Phase 2 Terminated
NCT02684071 2020-01-10
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Phase 2 Terminated
NCT00003194 2019-04-05
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Seattle Children's Hospital
Phase 1 Terminated
NCT02500459 2019-03-01
Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT00315211 2018-08-20
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
Aultman Health Foundation
Phase 2 Terminated
NCT00005029 2018-04-12
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Terminated
NCT00720096 2018-01-02
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Terminated
NCT00287859 2017-11-29
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00158886 2017-11-14
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
GlaxoSmithKline
Phase 1 Terminated
NCT02100007 2017-10-02
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Phase 1/2 Terminated
NCT00004221 2017-08-09
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
GOG Foundation
Phase 2 Terminated
NCT00808899 2017-05-30
Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02107378 2016-11-30
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Terminated
NCT01003938 2016-06-30
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NYU Langone Health
Phase 2 Terminated
NCT00087048 2016-03-22
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00526799 2016-03-03
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Hoosier Cancer Research Network
Phase 1/2 Terminated
NCT00812266 2016-01-26
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Danish Oncological Lung Cancer Group
Phase 3 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00313612 2015-11-27
Oxaliplatin and Topotecan in Advance Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT00002948 2014-07-02
High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Yale University
Phase 1 Terminated
NCT00107471 2013-12-10
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
Children's Oncology Group
Phase 1/2 Terminated
NCT00003382 2013-06-10
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
GOG Foundation
Phase 1 Terminated
NCT00697476 2013-05-29
Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
Istituto Clinico Humanitas
Phase 1/2 Terminated
NCT00003156 2013-04-11
Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus
GOG Foundation
Phase 2 Terminated
NCT00006032 2012-12-11
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01177501 2012-11-19
ITOV04
Assistance Publique - HĂ´pitaux de Paris
Phase 1 Terminated
NCT00005612 2012-09-26
ETC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00112619 2011-06-30
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
Pediatric Brain Tumor Consortium
Phase 1 Terminated
NCT00888810 2009-04-28
TOPO-LAPA
Centre Francois Baclesse
Phase 2 Terminated
NCT00322920 2008-02-15
Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer
University of Alabama at Birmingham
Phase 1 Terminated
NCT00194935 2006-09-13
Weekly Topotecan Therapy in Patients With Ovarian Cancer
Weill Medical College of Cornell University
Phase 2 Terminated